WHO WE ARE

We are a dual-listed (Euronext Brussels and NASDAQ: TIG) biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions in areas of high unmet medical need.

29 June 2017

TiGenix opens US headquarters in Cambridge, MA (ENNLFRES)

23 June 2017

TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland (ENNLFR ES)

UPCOMING EVENTS

  • INVESTORS AND PARTNERING
  • SCIENTIFIC AND OTHERS

SHARE PRICE

NASDAQ
21.07 USD
Change (%):
0.05 (0.24%)
BRU
0.91 EUR
Change (%):
0.00 (0.22%)